Definitive Healthcare (NASDAQ:DH) Trading Down 1.5%

Definitive Healthcare Corp. (NASDAQ:DH) shares traded down 1.5% during mid-day trading on Wednesday . The company traded as low as $5.34 and last traded at $5.35. 144,979 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 737,135 shares. The stock had previously closed at $5.43.

Analyst Upgrades and Downgrades

Several research firms have commented on DH. William Blair restated an “outperform” rating on shares of Definitive Healthcare in a report on Tuesday, May 14th. Stifel Nicolaus lowered their price target on shares of Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Canaccord Genuity Group reduced their price objective on Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, May 8th. Morgan Stanley downgraded Definitive Healthcare from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $11.50 to $9.00 in a report on Wednesday, May 8th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Definitive Healthcare from $10.00 to $7.00 and set a “hold” rating for the company in a report on Thursday, May 9th. Nine investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.94.

Definitive Healthcare Stock Down 0.2 %

The company has a quick ratio of 2.30, a current ratio of 2.30 and a debt-to-equity ratio of 0.20. The company has a fifty day simple moving average of $5.74 and a 200 day simple moving average of $7.67. The firm has a market capitalization of $629.75 million, a P/E ratio of -3.02, a P/E/G ratio of 3.87 and a beta of 1.30.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Tuesday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.04). The firm had revenue of $63.48 million during the quarter, compared to the consensus estimate of $64.00 million. Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. On average, equities analysts expect that Definitive Healthcare Corp. will post 0.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. lifted its holdings in Definitive Healthcare by 41.7% in the third quarter. Envestnet Asset Management Inc. now owns 383,151 shares of the company’s stock valued at $3,061,000 after acquiring an additional 112,718 shares during the period. OLD National Bancorp IN boosted its holdings in shares of Definitive Healthcare by 14.5% in the third quarter. OLD National Bancorp IN now owns 20,613 shares of the company’s stock worth $165,000 after buying an additional 2,609 shares during the last quarter. Wesbanco Bank Inc. purchased a new position in shares of Definitive Healthcare in the third quarter worth approximately $551,000. Vanguard Group Inc. grew its position in Definitive Healthcare by 6.2% during the third quarter. Vanguard Group Inc. now owns 4,331,543 shares of the company’s stock valued at $34,609,000 after buying an additional 254,726 shares during the period. Finally, Baker Tilly Wealth Management LLC increased its holdings in Definitive Healthcare by 19.7% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 59,956 shares of the company’s stock valued at $596,000 after buying an additional 9,885 shares during the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.